Cargando…
Newly developed 3D in vitro models to study tumor–immune interaction
Immunotherapy as a rapidly developing therapeutic approach has revolutionized cancer treatment and revitalized the field of tumor immunology research. 3D in vitro models are emerging as powerful tools considering their feature to maintain tumor cells in a near-native state and have been widely appli...
Autores principales: | Mu, Peiyuan, Zhou, Shujuan, Lv, Tao, Xia, Fan, Shen, Lijun, Wan, Juefeng, Wang, Yaqi, Zhang, Hui, Cai, Sanjun, Peng, Junjie, Hua, Guoqiang, Zhang, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074642/ https://www.ncbi.nlm.nih.gov/pubmed/37016422 http://dx.doi.org/10.1186/s13046-023-02653-w |
Ejemplares similares
-
Organoid based personalized medicine: from bench to bedside
por: Li, Yaqi, et al.
Publicado: (2020) -
Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E)
por: Chen, Yajie, et al.
Publicado: (2023) -
Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)
por: Wang, Yaqi, et al.
Publicado: (2022) -
Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation
por: Wang, Yaqi, et al.
Publicado: (2022) -
TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial
por: Wan, Juefeng, et al.
Publicado: (2023)